Heinrichs L, Fluegen G, Loosen S, Loberg C, Wittig L, Quaas A
BJC Rep. 2024; 2(1):72.
PMID: 39323978
PMC: 11420066.
DOI: 10.1038/s44276-024-00094-2.
Seliem M, Mohamadin A, El-Sayed M, Ismail Y, El-Husseiny A
Breast Cancer Res Treat. 2024; 208(1):57-66.
PMID: 38916819
PMC: 11452551.
DOI: 10.1007/s10549-024-07393-9.
Okuda Y, Shimura T, Abe Y, Iwasaki H, Nishigaki R, Fukusada S
J Gastroenterol. 2024; 59(7):572-585.
PMID: 38836911
DOI: 10.1007/s00535-024-02110-1.
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L
JCO Precis Oncol. 2024; 8:e2300702.
PMID: 38662983
PMC: 11513442.
DOI: 10.1200/PO.23.00702.
Klumper N, Tran N, Zschabitz S, Hahn O, Buttner T, Roghmann F
J Clin Oncol. 2024; 42(20):2446-2455.
PMID: 38657187
PMC: 11227306.
DOI: 10.1200/JCO.23.01983.
The lncRNAs Gas5, MALAT1 and SNHG8 as diagnostic biomarkers for epithelial malignant pleural mesothelioma in Egyptian patients.
Elkahwagy D, Kiriacos C, Sobeih M, Khorshid O, Mansour M
Sci Rep. 2024; 14(1):4823.
PMID: 38413635
PMC: 10899637.
DOI: 10.1038/s41598-024-55083-9.
Physicians' Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care.
Thannickal H, Eltoum N, Henderson N, Wallner L, Wagner L, Wolff A
Oncologist. 2023; 29(1):e38-e46.
PMID: 37405703
PMC: 10769784.
DOI: 10.1093/oncolo/oyad198.
Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.
Edland K, Tjensvoll K, Oltedal S, Dalen I, Lapin M, Garresori H
Mol Oncol. 2023; 17(9):1857-1870.
PMID: 37341038
PMC: 10483602.
DOI: 10.1002/1878-0261.13472.
High-throughput proteomics profiling-derived signature associated with chemotherapy response and survival for stage II/III colorectal cancer.
Ye S, Cheng Y, Li P, Zhang L, Zhang L, Huang Y
NPJ Precis Oncol. 2023; 7(1):50.
PMID: 37258779
PMC: 10232411.
DOI: 10.1038/s41698-023-00400-0.
Quantification of subtype purity in Luminal A breast cancer predicts clinical characteristics and survival.
Kumar N, Gann P, McGregor S, Sethi A
Breast Cancer Res Treat. 2023; 200(2):225-235.
PMID: 37209182
PMC: 10241706.
DOI: 10.1007/s10549-023-06961-9.
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment.
Valenza C, Taurelli Salimbeni B, Santoro C, Trapani D, Antonarelli G, Curigliano G
Cancers (Basel). 2023; 15(3).
PMID: 36765724
PMC: 9913599.
DOI: 10.3390/cancers15030767.
The prognostic value of separate lymphatic invasion and vascular invasion in oesophageal squamous cell carcinoma: a meta-analysis and systematic review.
Wang A, Tan Y, Wang S, Chen X
BMC Cancer. 2022; 22(1):1329.
PMID: 36536299
PMC: 9764535.
DOI: 10.1186/s12885-022-10441-6.
REMARK guidelines for tumour biomarker study reporting: a remarkable history.
Hayes D, Sauerbrei W, McShane L
Br J Cancer. 2022; 128(3):443-445.
PMID: 36476656
PMC: 9938190.
DOI: 10.1038/s41416-022-02046-4.
Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis.
Basyuni S, Nugent G, Ferro A, Barker E, Reddin I, Jones O
Sci Rep. 2022; 12(1):20776.
PMID: 36456616
PMC: 9715723.
DOI: 10.1038/s41598-022-25291-2.
Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study.
Nordgard O, Lapin M, Tjensvoll K, Oltedal S, Edland K, Neverdahl N
BMC Cancer. 2022; 22(1):609.
PMID: 35659265
PMC: 9166481.
DOI: 10.1186/s12885-022-09714-x.
CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer.
Luque M, Cristobal I, Sanz-Alvarez M, Santos A, Zazo S, Eroles P
J Clin Med. 2022; 11(6).
PMID: 35329936
PMC: 8955826.
DOI: 10.3390/jcm11061610.
MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients.
Santos A, Cristobal I, Rubio J, Carames C, Luque M, Sanz-Alvarez M
Int J Mol Sci. 2022; 23(4).
PMID: 35216319
PMC: 8875596.
DOI: 10.3390/ijms23042203.
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer.
Nilsen A, Hillestad T, Skingen V, Aarnes E, Fjeldbo C, Hompland T
Mol Oncol. 2022; 16(6):1402-1419.
PMID: 35064630
PMC: 8936520.
DOI: 10.1002/1878-0261.13184.
A Novel Urinary miRNA Biomarker for Early Detection of Colorectal Cancer.
Iwasaki H, Shimura T, Kitagawa M, Yamada T, Nishigaki R, Fukusada S
Cancers (Basel). 2022; 14(2).
PMID: 35053622
PMC: 8773893.
DOI: 10.3390/cancers14020461.
Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
Luque M, Sanz-Alvarez M, Santamaria A, Zazo S, Cristobal I, de la Fuente L
Int J Mol Sci. 2021; 22(24).
PMID: 34948097
PMC: 8706990.
DOI: 10.3390/ijms222413297.
